Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke (ANGONG TRIAL)

Acute Ischemic Stroke Clinical Trial

Official title:

Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04475328
• Other study ID #: PUMCH-AGNH2020
• Status: Completed
• Phase: Phase 3
• Start date: October 1, 2020
• Est. completion date: July 30, 2022

Study information

• Verified date: September 2023
• Source: Peking Union Medical College Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

AngongNiuhuang pill has obvious effects on the cardiovascular and cerebrovascular diseases. Pharmacological experiments confirmed that AngongNiuhuang pill can protect blood-brain barrier, inhibit capillary permeability, improve the tolerance of cerebral ischemia and hypoxia, reduce oxidative stress injury, thus protecting brain tissue. Clinical studies have also confirmed that AngongNiuhuang pill can increase the GCS score, reduce coma, improve nerve function defect and promote nerve function recovery. The primary purpose of this trial was to evaluate the difference in the volume of cerebral infarction and cerebral edema between Angong Niuhuang pill and placebo in patients with ischemic stroke at 14 days compared with the baseline.

Description:

This trial is a prospective, randomized, double-blinded, placebo parallel controlled, multicenter trial. Patients who met the inclusion and exclusion criteria will be randomized 1:1 into two groups after offering informed content: 1) one group will receive AngongNiuhuang pill 1pill qd/day for 5-day; 2) the other group will receive Placebo of AngongNiuhuang pill 1pill qd/day for 5-day. The primary purpose of this trial was to evaluate the difference in the volume of cerebral infarction and cerebral edema between Angong Niuhuang pill and placebo in patients with ischemic stroke at 14 days compared with the baseline. The study was consisted of six visits, including the day of randomization, 2 days, 3-6 days, 7 days (the endap time of the therapy), 14 days, and 90 days (the endap time of the follow-up). Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment neurological function rating scale will be recorded during the program. The period of the trial is from August 2020 to October 2021, and 120 subjects are planned to be recruited from 10 centers in China. All the related investigative organizations and individuals will obey the Declaration of Helsinki and Chinese Guard-cell protoplast (GCP) standard. A Data and Safety Monitoring Board (DSMB) will regularly monitor safety during the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: July 30, 2022
• Est. primary completion date: May 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female participates aged 40-80 years.

2. Diagnosis with acute ischemic stroke.

3. Diagnosis with acute cerebral infarctions of internal carotid artery system.

4. 10= Baseline NIHSS <20.

5. Time of onset =36h.

6. Provision of informed consent.

Exclusion Criteria:

1. Not suitable for taking this medicine according to the judgement of consulting traditional Chinese medical doctor.

2. Suffering from intracranial tumors, encephalitis, subarachnoid hemorrhage and other brain organic diseases.

3. Patients with hemorrhagic transformation after cerebral infarction.

4. Received or planned to receive endovascular treatment, including thrombectomy, ultra early thrombectomy and stenting.

5. Received or planned to receive decompression craniectomy.

6. With mRS score >1 before onset of this episode.

7. Participates who cannot tolerate the MRI scans, such as Using a pacemaker or automatic defibrillator or having claustrophobia.

8. With thrombocytopenia (<100 x10^9/L), hematologic diseases or other systemic bleeding tendency.

9. With Alanine transaminase or Aspartate aminotransferase >1.5 times than normal upper limit or Creatinine >1.5 times than normal upper limit.

10. Allergic to ingredients of AngongNiuhuang pill.

11. Received AngongNiuhuang pill within 1 month.

12. Participates who plan to become pregnant within 3 months, or women of childbearing age with negative pregnancy test but refuse to accept contraception; during pregnancy or lactation.

13. Participates in other clinical trials within 30 days before randomization or currently involved in other clinical trails.

14. Participates with a life expectancy less than 3 months.

15. Incapable to follow this study due to mental illness, cognitive or emotional disorders.

16. Participates are not eligible for this clinical trial as evaluated by the investigators.

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Drug:
• AngongNiuhuang pill
This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
• Placebo of AngongNiuhuang pill
This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.

Other:
• Standard treatment
The other treatments according to guidelines for standard treatment of acute ischemic stroke

Locations

Country	Name	City	State
China	Department of Neurology,Peking Union Medical College Hospital,Shuaifuyuan 1,Dong Cheng District. Beijing	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cerebral infarction volume	Changes in cerebral infarction volume on Day 14 of the treatment from baseline.	14 days
Primary	Cerebral edema volume	Changes in cerebral edema volume on Day 14 of the treatment from baseline.	14 days
Primary	The proportion of the patients with Severity Adverse Events within 90 days of the treatment.	Severity Adverse Events	90 days
Secondary	Cerebral infarction volume	Changes in cerebral infarction volume on Day 90 of the treatment from baseline.	90 days
Secondary	Cerebral edema volume	Changes in cerebral edema volume on Day 90 of the treatment from baseline.	90 days
Secondary	The proportion of patients with Modified Rankin Scale (mRS) score = 2 point on the Day 14 and 90 of treatment.	Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 - No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead. The mRS scores between 3 to 6 points are considered to be poor functional outcome.	14 days, 90 days
Secondary	Changes in NIHSS score on Day 14 and 90 of the treatment from baseline.	The NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.	14 days, 90 days
Secondary	Changes in Glasgow Coma Score (GCS) on the Day 7 and 14 of the treatment from baseline.	We will use the GCS score to evaluate the degree of coma. The GCS have three domain items (open-eye response, speech response, and movement). The maximum possible score is 15, with the minimum score being a 3.	7 days, 14 days
Secondary	Changes of biomarker (hs-CRP)	Evaluation of the change in hs-CRP on Day 7 of the treatment.	7 days
Secondary	Changes of biomarker (MMP-9)	Evaluation of the change in MMP-9 on Day 7 of the treatment.	7 days
Secondary	Changes of biomarker (S-100B)	Evaluation of the change in S-100B on Day 7 of the treatment.	7 days
Secondary	Changes of biomarker (NSE)	Evaluation of the change in NSE on Day 7 of the treatment.	7 days
Secondary	The proportion of the patients with Severity Adverse Events within 7 days of the treatment.	Severity Adverse Events	7 days
Secondary	Changes in toxicology index including mercury and arsenic on Day 7 of the treatment.	toxicology index	7 days
Secondary	The proportion of the patients with Adverse Events within 7 and 90 days of the treatment.	Adverse Events	7 days, 90 days
Secondary	The proportion of the patients with All-cause mortality within 7 and 90 days of the treatment.	All-cause mortality	7 days, 90 days
Secondary	The proportion of the patients with Combined vascular events within 7 and 90 days of the treatment.	Combined vascular events	7 days, 90 days